Universal Biosensors (UBI) is a medical diagnostics company focused on the research, development and manufacture of diagnostic test systems for point-of-care (POC) professional and home use. The point-of-care diagnostic market is worth US$15 billion a year and growing.
UBI began its journey focusing on the research, development and manufacture of devices for the diagnostic POC market using UBI’s core technology of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system that rapidly and accurately measures different biomarkers in blood.
This innovative technology led UBI to develop a blood glucose monitoring product for LifeScan, Inc. (a Johnson & Johnson company) which was launched in 2010 under the global brand of OneTouch® Verio®. This was soon followed by the development of a Prothrombin Time (PT/INR) blood coagulation analyser and test strip for Siemens Healthcare which was launched in 2014 under the global brand of Xprecia Stride™, to help patients taking the anticoagulant drug Warfarin manage their medication.
UBI has also developed a blood glucose monitoring product that is being commercialised globally by LifeScan, Inc. (a Johnson & Johnson company) under the OneTouch® Verio® brand.
UBI’s innovative electrochemical sensor platform is being applied to a range of other medical diagnostic applications. Building upon the success of these globally launched products, UBI continues to focus on the diagnostic POC market and is now exploring the opportunities this technology offers of speed, ease of use, reliability, accuracy at a low cost in alternative industries.
The company is listed on the Australian Securities Exchange under the ticker “UBI”, and operates from its manufacturing and R&D facility in Melbourne, Australia.